GSK signs £3.8bn-equivalent of loans tied to RFRs

GlaxoSmithKlein, the UK pharmaceutical company, has refinanced dollar and sterling loans using risk-free rates, in one of the biggest transactions yet to avoid using Libor as the margin benchmark.